LXRX Live signals | Maximize Profits with Getagraph.com

BUY 123647 min ago

@ $3.29

Issued: 14 Feb 2024 @ 13:44

Return: -44.53%

Previous signal: Feb 14 - 09:31

Previous signal: Sell

Return: 4.44 %

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 11:31):

Stats
Today's Volume	761 439
Average Volume	4.50M
Market Cap	449.38M
EPS	$0 ( 2024-05-07 )
Next earnings date	( $-0.180 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.20
ATR14	$0.00700 (0.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-28	Swain Judith L	Buy	8 032	Common Stock
2024-04-28	Swain Judith L	Sell	8 032	Restricted Stock Units
2024-04-28	Sobecki Christopher J	Buy	8 032	Common Stock
2024-04-28	Sobecki Christopher J	Sell	8 032	Restricted Stock Units
2024-04-28	Lefkowitz Robert J Md	Buy	8 032	Common Stock

INSIDER POWER
77.52
Last 98 transactions
Buy: 8 163 755 \| Sell: 972 585

Volume Correlation

Long: -0.43 (neutral)

Short: -0.89 (strong negative)

Signal:(40.674) Neutral

Lexicon Pharmaceuticals Correlation

10 Most Positive Correlations
FAT	0.892
MORF	0.876
PCVX	0.869
ADVM	0.864
GANX	0.864
MREO	0.857
BNIXU	0.851
BASE	0.849
FCBP	0.839
CSX	0.835

10 Most Negative Correlations
BFRI	-0.838
PSHG	-0.813
RTPY	-0.803

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lexicon Pharmaceuticals Correlation - Currency/Commodity

0.42
( neutral )

0.37
( neutral )

0.00
( neutral )

-0.02
( neutral )

0.00
( neutral )

0.11
( neutral )

Lexicon Pharmaceuticals Financials

Annual	2023
Revenue:	$1.20M
Gross Profit:	$565 000 (46.93 %)
EPS:	$-0.800

FY	2023
Revenue:	$1.20M
Gross Profit:	$565 000 (46.93 %)
EPS:	$-0.800

FY	2022
Revenue:	$139 000
Gross Profit:	$-288 000 (-207.19 %)
EPS:	$-0.620

FY	2021
Revenue:	$298 000
Gross Profit:	$298 000 (100.00 %)
EPS:	$-0.602

Financial Reports:

No articles found.

Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.